IMPROVEMENT IN FATIGUE WITH MIRIKIZUMAB THERAPY IS ASSOCIATED WITH CLINICAL REMISSION AND PAIN IMPROVEMENTS BUT NOT WITH ENDOSCOPIC RESPONSE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE

Miguel Reguiero  ¹     Monika Fischer  ²     David T. Rubin  ³     Toshifumi Hibi  ⁴     Peter Bossuyt  ⁵     Pascal Juillerat  ⁶     Paul Pollack  ⁷     Xian Zhou  ⁸     Marijana Protic  ⁹     Theresa Hunter Gibble  ¹⁰     Lai Shan Chan  ¹⁰     Hilde Carlier  ¹¹     Pieter Hindryckx  ^12    
1 Cleveland Clinic, Cleveland, United States
² IUPUI, Indianapolis, United States
³ University of Chicago Medicine, Chicago, United States
⁴ Kitasato Institute Hospital IBD Research and Treatment, Tokyo, Japan
⁵ Imelda General Hospital, Bonheiden, Belgium
⁶ Inselspital Bern University Clinic for Visceral Surgery and Medicin, Bern, Switzerland
⁷ Consultant, Bexley, OH, United States
⁸ Syneos Health, Morrisville, United States
⁹ Eli Lilly & Company, Vernier, Genève
¹⁰ Eli Lilly and Company, Indianapolis, United States
¹¹ Eli Lilly and Company, Brussels, Belgium
¹² Ghent University Hospital Dept. of Gastroenterology, Ghent, Belgium

Session
IBD (Posters)

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)